Gilead Sciences, Inc. (GILD) Given Consensus Rating of “Buy” by Brokerages

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) have been assigned a consensus rating of “Buy” from the twenty-seven analysts that are currently covering the company, MarketBeat reports. Twelve equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $88.35.

Several equities research analysts recently commented on GILD shares. Mizuho reaffirmed a “buy” rating and set a $94.00 target price on shares of Gilead Sciences in a research note on Friday, August 10th. Piper Jaffray Companies set a $85.00 target price on Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, September 12th. BidaskClub cut Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, August 18th. Zacks Investment Research cut Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 25th. Finally, ValuEngine cut Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Monday, August 20th.

Shares of GILD traded down $0.33 during mid-day trading on Wednesday, reaching $75.91. 163,298 shares of the company were exchanged, compared to its average volume of 7,359,248. Gilead Sciences has a 52 week low of $64.27 and a 52 week high of $89.54. The company has a debt-to-equity ratio of 1.23, a current ratio of 3.00 and a quick ratio of 2.92. The company has a market capitalization of $100.09 billion, a price-to-earnings ratio of 8.87, a price-to-earnings-growth ratio of -3.92 and a beta of 1.01.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, July 25th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.56 by $0.35. Gilead Sciences had a return on equity of 41.57% and a net margin of 9.52%. The company had revenue of $5.65 billion during the quarter, compared to the consensus estimate of $5.20 billion. During the same period last year, the company earned $2.56 earnings per share. The firm’s revenue was down 20.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Gilead Sciences will post 6.56 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 27th. Shareholders of record on Friday, September 14th were paid a $0.57 dividend. The ex-dividend date was Thursday, September 13th. This represents a $2.28 dividend on an annualized basis and a yield of 3.00%. Gilead Sciences’s dividend payout ratio (DPR) is presently 26.64%.

In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 4th. The stock was sold at an average price of $74.16, for a total value of $3,708,000.00. Following the completion of the sale, the director now owns 3,067,762 shares of the company’s stock, valued at $227,505,229.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 150,000 shares of company stock valued at $11,502,500 in the last three months. Insiders own 1.16% of the company’s stock.

A number of institutional investors have recently made changes to their positions in GILD. Archford Capital Strategies LLC purchased a new position in shares of Gilead Sciences during the first quarter valued at approximately $106,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new position in shares of Gilead Sciences during the second quarter valued at approximately $132,000. Brand Asset Management Group Inc. purchased a new position in shares of Gilead Sciences during the second quarter valued at approximately $139,000. Wealthsource Partners LLC purchased a new position in shares of Gilead Sciences during the second quarter valued at approximately $206,000. Finally, Ballast Inc. purchased a new position in shares of Gilead Sciences during the first quarter valued at approximately $207,000. 77.99% of the stock is owned by hedge funds and other institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Further Reading: What is a stock buyback?

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply